Help people with airway obstructive diseases breathe easily

and prevent progressive lung damage & respiratory failure

Cila Therapeutics

A clinic-ready stage, biotechnology company developing new inhaled therapies for the treatment of a rare genetic disorder, Primary Ciliary Dyskinesia (PCD), and other respiratory diseases.

Automation-of-complex-synthetic-biologic
shutterstock_198680741.jpg

"To date, no pharmacological intervention has been approved for Primary Ciliary Dyskinesia (PCD) indication

Source: https://pcdfoundation.org

Listening to baby's lungs
Respiratory inhalation, personal care, h

~1/10000

Live births are affected by PCD

~95%

 Progress to

bronchiectasis

~25%

PCD patients experience life-threatening respiratory failure and some require lung transplant

0

Drugs approved for PCD indication

What is Primary Ciliary Dyskinesia (PCD)?

PCD is a rare disease caused by multiple genetic mutations involving fingerlike projections on airway cells known as "Cilia". It is estimated to affect ~1/10000 birth in the US.

 

Normal mucus traps pathogens and Cilia move to clear it. In PCD patients, due to genetic reasons, Cilia are dysfunctional so mucus builds up and forms "mucus plugs". These plugs clog airways and initiate a vicious cycle of recurrent infection, airway damage, permanent lung damage, and progression to bronchiectasis.

Picture1.png

Source: NHLBI website 

Screen Shot 2020-07-29 at 3.07.45 PM.png

Source: Mirra et al., 2017. Frontiers in Pediatrics. 

Symptoms

Patients experience chronic cough, respiratory problems, and recurrent ear and lung infections from birth onwards. A significant number of PCD cases experience life-threatening respiratory failure and some require lung transplantation. Exacerbation of respiratory distress leads to frequent ER visits, hospitalization, poor quality of life for patients, and a huge economic burden on families and the healthcare system. 

 
 
Our pipeline

CILA has a robust early-stage pipeline 

COMPOUND

DISCOVERY

INDICATION

PRECLINICAL

PHASE I

PHASE II

PHASE III

pipeline.png
pipeline.png
pipeline.png

CIL-005

CIL-006

CIL-008 + CIL-005

CIL-009

CIL-010

PCD

Bronchiectasis

CF

PCD

TBD

pipeline.png
pipeline.png
 

Patients resources

FOUNDATIONS FOR OBSTRUCTIVE AIRWAYS DISEASES

Picture1.png
copd-foundation.png
6ee7ab20-3217-4328-b14e-44338f60d10c.jpg

ADDITIONAL RESOURCES

168-american lunch association of illino
1flcfl3260.jpg
CilaTherapeutics-logo_edited_edited_edit
LINKS
CONTACT
SOCIAL
  • White LinkedIn Icon

© 2020 by Cila Therapeutics